Skip to main content
Erschienen in: Annals of Surgical Oncology 4/2008

01.04.2008 | Hepatic and Pancreatic Tumors

Pancreatic Metastasis From Renal Cell Carcinoma: Which Patients Benefit From Surgical Resection?

verfasst von: Alessandro Zerbi, MD, Enrico Ortolano, MD, Gianpaolo Balzano, MD, Anna Borri, MD, Aldo Alberto Beneduce, MD, Valerio Di Carlo, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 4/2008

Einloggen, um Zugang zu erhalten

Abstract

Background

Pancreas is a possible site of metastases from renal cell carcinoma (RCC). The aim of this study was to define the role of surgery in their treatment.

Methods

We retrospectively analyzed 36 patients with pancreatic metastasis from RCC observed between January 1998 and February 2006. Patients were categorized into three risk groups according to the modified Memorial Sloan-Kettering prognostic factors model.

Results

Resective surgery was performed in 23 patients, as follows: 11 distal pancreatectomy, 5 enucleation, 4 pancreatoduodenectomy, 2 total pancreatectomy, and 1 middle pancreatectomy. No perioperative mortality was observed; the morbidity rate was 47.8%. All patients who underwent resection belonged to the favorable risk group. Surgical resection was excluded in 13 cases because of locally advanced disease (2 cases) or extrapancreatic disease (11 cases); 5 of these patients were at favorable, 7 at intermediate, and 1 at poor risk. In patients undergoing surgery, the 5-year actuarial survival rate was 88%, and median disease-free survival was 44 months. Patients who did not undergo surgery had a 5-year survival rate of 47%, with a median survival time of 27 months (P = .02).

Conclusions

Patients with pancreatic metastases from RCC belonging to a favorable risk group are candidates for resection, even in the presence of another metastatic site or multifocal pancreatic disease.
Literatur
1.
Zurück zum Zitat Roland CF, van Heerden JA. Nonpancreatic primary tumors with metastasis to the pancreas. Surg Gynecol Obstet 1989;168:345–7PubMed Roland CF, van Heerden JA. Nonpancreatic primary tumors with metastasis to the pancreas. Surg Gynecol Obstet 1989;168:345–7PubMed
2.
Zurück zum Zitat Z’graggen K, Fernandez-del Castillo C, Rattner DW, et al. Metastases to the pancreas and their surgical extirpation. Arch Surg 1998;133:413–8PubMedCrossRef Z’graggen K, Fernandez-del Castillo C, Rattner DW, et al. Metastases to the pancreas and their surgical extirpation. Arch Surg 1998;133:413–8PubMedCrossRef
3.
Zurück zum Zitat Faure JP, Tuech JJ, Richer JP, et al. Pancreatic metastasis of renal cell carcinoma: presentation, treatment and survival. J Urol 2001;165:20–2PubMedCrossRef Faure JP, Tuech JJ, Richer JP, et al. Pancreatic metastasis of renal cell carcinoma: presentation, treatment and survival. J Urol 2001;165:20–2PubMedCrossRef
4.
Zurück zum Zitat Bassi C, Butturini G, Falconi M, et al. High recurrence rate after atypical resection for pancreatic metastases from renal cell carcinoma. Br J Surg 2003;90:555–9PubMedCrossRef Bassi C, Butturini G, Falconi M, et al. High recurrence rate after atypical resection for pancreatic metastases from renal cell carcinoma. Br J Surg 2003;90:555–9PubMedCrossRef
5.
Zurück zum Zitat Sellner F, Tykalsky N, De Santis M, et al. Solitary and multiple isolated metastases of clear cell carcinoma to the pancreas: an indication for pancreatic surgery. Ann Surg Oncol 2006;13:75–85PubMedCrossRef Sellner F, Tykalsky N, De Santis M, et al. Solitary and multiple isolated metastases of clear cell carcinoma to the pancreas: an indication for pancreatic surgery. Ann Surg Oncol 2006;13:75–85PubMedCrossRef
6.
Zurück zum Zitat Thompson L, Heffess C. Renal cell carcinoma to the pancreas in surgical pathology material. A clinicopathological study with 21 cases with a review of the literature. Cancer 2000;89:1076–88PubMedCrossRef Thompson L, Heffess C. Renal cell carcinoma to the pancreas in surgical pathology material. A clinicopathological study with 21 cases with a review of the literature. Cancer 2000;89:1076–88PubMedCrossRef
7.
Zurück zum Zitat Sohn TA, Yeo CJ, Cameron JL, et al. Renal cell carcinoma metastatic to the pancreas: results of surgical management. J Gastrointest Surg 2001;5:346–51PubMedCrossRef Sohn TA, Yeo CJ, Cameron JL, et al. Renal cell carcinoma metastatic to the pancreas: results of surgical management. J Gastrointest Surg 2001;5:346–51PubMedCrossRef
8.
Zurück zum Zitat Law CH, Wei AC, Hanna SS, et al. Pancreatic resection for metastatic renal cell carcinoma: presentation, treatment, and outcome. Ann Surg Oncol 2003;10:922–6PubMedCrossRef Law CH, Wei AC, Hanna SS, et al. Pancreatic resection for metastatic renal cell carcinoma: presentation, treatment, and outcome. Ann Surg Oncol 2003;10:922–6PubMedCrossRef
9.
Zurück zum Zitat Sperti C, Pasquali C, Liessi G, et al. Pancreatic resection for metastatic tumors to the pancreas. J Surg Oncol 2003;83:161–6PubMedCrossRef Sperti C, Pasquali C, Liessi G, et al. Pancreatic resection for metastatic tumors to the pancreas. J Surg Oncol 2003;83:161–6PubMedCrossRef
10.
Zurück zum Zitat Kassabian A, Stein J, Jabbour N, et al. Renal cell carcinoma metastatic to the pancreas: a single-institution series and review of the literature. Urology 2000;56:211–5PubMedCrossRef Kassabian A, Stein J, Jabbour N, et al. Renal cell carcinoma metastatic to the pancreas: a single-institution series and review of the literature. Urology 2000;56:211–5PubMedCrossRef
11.
Zurück zum Zitat Sotiropoulos GC, Lang H, Liu C, et al. Surgical treatment of pancreatic metastases of renal cell carcinoma. J Pancreas 2005;6:339–43 Sotiropoulos GC, Lang H, Liu C, et al. Surgical treatment of pancreatic metastases of renal cell carcinoma. J Pancreas 2005;6:339–43
12.
Zurück zum Zitat Wente MN, Kleeff J, Esposito I, et al. Renal cancer cell metastasis into the pancreas. A single-center experience and overview of the literature. Pancreas 2005;30:218–22PubMedCrossRef Wente MN, Kleeff J, Esposito I, et al. Renal cancer cell metastasis into the pancreas. A single-center experience and overview of the literature. Pancreas 2005;30:218–22PubMedCrossRef
13.
Zurück zum Zitat Atkins MB, Avigan DE, Bukowski RM, et al. Innovations and challenges in renal cancer: consensus statement from the first international conference. Clin Cancer Res 2004;10:6277s–81sPubMedCrossRef Atkins MB, Avigan DE, Bukowski RM, et al. Innovations and challenges in renal cancer: consensus statement from the first international conference. Clin Cancer Res 2004;10:6277s–81sPubMedCrossRef
14.
Zurück zum Zitat Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17:2530–40PubMed Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17:2530–40PubMed
15.
Zurück zum Zitat Atzpodien J, Royston P, Wandert T, et al, and the DGCIN–German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group. Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer 2003;88:348–53PubMedCrossRef Atzpodien J, Royston P, Wandert T, et al, and the DGCIN–German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group. Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer 2003;88:348–53PubMedCrossRef
16.
Zurück zum Zitat Leibovich BC, Cheville JC, Lohse CM, et al. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol 2005;174:1759–63PubMedCrossRef Leibovich BC, Cheville JC, Lohse CM, et al. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol 2005;174:1759–63PubMedCrossRef
17.
Zurück zum Zitat Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004;22:454–63PubMedCrossRef Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004;22:454–63PubMedCrossRef
18.
Zurück zum Zitat Mekhail TM, Abou-Jawde RM, Boumerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005;23:832–41CrossRef Mekhail TM, Abou-Jawde RM, Boumerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005;23:832–41CrossRef
19.
Zurück zum Zitat Bassi C, Dervenis C, Butturini G, et al. Postoperative pancreatic fistula: an International Study Group (ISGPF) definition. Surgery 2005;138:8–13PubMedCrossRef Bassi C, Dervenis C, Butturini G, et al. Postoperative pancreatic fistula: an International Study Group (ISGPF) definition. Surgery 2005;138:8–13PubMedCrossRef
20.
Zurück zum Zitat Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–81CrossRef Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–81CrossRef
21.
22.
Zurück zum Zitat Javidan J, Stricker HJ, Tamboli P, et al. Prognostic significance of the 1997 TNM classification of renal cell carcinoma. J Urol 1999;162:1277–81PubMedCrossRef Javidan J, Stricker HJ, Tamboli P, et al. Prognostic significance of the 1997 TNM classification of renal cell carcinoma. J Urol 1999;162:1277–81PubMedCrossRef
23.
Zurück zum Zitat Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol 2001;166:1611–23PubMedCrossRef Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol 2001;166:1611–23PubMedCrossRef
24.
Zurück zum Zitat Janzen NK, Kim HL, Figlin RA, et al. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003;30:843–52PubMedCrossRef Janzen NK, Kim HL, Figlin RA, et al. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003;30:843–52PubMedCrossRef
25.
26.
27.
28.
Zurück zum Zitat Nakeeb A, Lillemoe KD, Cameron JL. The role of pancreaticoduodenectomy for locally recurrent or metastatic carcinoma to the periampullary region. J Am Coll Surg 1995;180:188–92PubMed Nakeeb A, Lillemoe KD, Cameron JL. The role of pancreaticoduodenectomy for locally recurrent or metastatic carcinoma to the periampullary region. J Am Coll Surg 1995;180:188–92PubMed
29.
Zurück zum Zitat Kierney PC, van Heerden JA, Segura JW, et al. Surgeon’s role in the management of solitary renal cell carcinoma metastases occurring subsequent to initial curative nephrectomy: an institutional review. Ann Surg Oncol 1994;1:345–52PubMedCrossRef Kierney PC, van Heerden JA, Segura JW, et al. Surgeon’s role in the management of solitary renal cell carcinoma metastases occurring subsequent to initial curative nephrectomy: an institutional review. Ann Surg Oncol 1994;1:345–52PubMedCrossRef
30.
Zurück zum Zitat Pogrebniak HW, Haas G, Linehan WM, et al. Renal cell carcinoma: resection of solitary and multiple metastases. Ann Thorac Surg 1992;54:33–8PubMedCrossRef Pogrebniak HW, Haas G, Linehan WM, et al. Renal cell carcinoma: resection of solitary and multiple metastases. Ann Thorac Surg 1992;54:33–8PubMedCrossRef
Metadaten
Titel
Pancreatic Metastasis From Renal Cell Carcinoma: Which Patients Benefit From Surgical Resection?
verfasst von
Alessandro Zerbi, MD
Enrico Ortolano, MD
Gianpaolo Balzano, MD
Anna Borri, MD
Aldo Alberto Beneduce, MD
Valerio Di Carlo, MD
Publikationsdatum
01.04.2008
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 4/2008
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-007-9782-0

Weitere Artikel der Ausgabe 4/2008

Annals of Surgical Oncology 4/2008 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.